Search

Your search keyword '"Vijayvergia N"' showing total 57 results

Search Constraints

Start Over You searched for: Author "Vijayvergia N" Remove constraint Author: "Vijayvergia N"
57 results on '"Vijayvergia N"'

Search Results

3. LBA26 SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)

4. 1141O Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses

6. 207P Palbociclib (P) in patients (pts) with solid tumors with CDK4 or CDK6 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study

11. Classification of pulmonary neuroendocrine tumors: New insights

13. 251P Phase II study of organ preservation (OP) using neoadjuvant chemotherapy (Ctx) and local excision (LE) in node-negative (NN) low rectal cancer (RC).

14. Classification of pulmonary neuroendocrine tumors: new insights

15. TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial.

16. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

17. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.

18. Liver Transplantation in a Woman with Mahvash Disease.

19. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.

20. The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership.

21. Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms.

22. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.

23. Incidence of asymptomatic COVID-19 positivity in cancer patients and effects on therapy.

24. Venous thromboembolism in metastatic pancreatic cancer.

25. Comparative Outcomes of Second-line Topoisomerase-I Inhibitor Therapies on Neuroendocrine Carcinoma.

26. Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors.

27. A Virtual Tumor Board Platform: A Way to Enhance Decision-Making for Complex Malignancies.

28. Incidence of asymptomatic COVID-19 positivity in cancer patients and effects on therapy.

29. Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC).

31. A Subset of Large Cell Neuroendocrine Carcinomas in the Gastroenteropancreatic Tract May Evolve from Pre-existing Well-Differentiated Neuroendocrine Tumors.

32. Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.

33. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

34. Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms.

35. First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer.

36. Feasibility of Fitness Tracker Usage to Assess Activity Level and Toxicities in Patients With Colorectal Cancer.

37. Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms.

38. Investigating disparities: the effect of social environment on pancreatic cancer survival in metastatic patients.

39. Chemotherapy use and survival in older adults with metastatic pancreatic cancer in the combination therapy era.

40. Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials.

41. Classification of pulmonary neuroendocrine tumors: new insights.

42. BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations.

43. Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer.

44. Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?

45. Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study.

46. Patterns of care and outcomes of older versus younger patients with metastatic pancreatic cancer: A Fox Chase Cancer Center experience.

47. Survivorship in Non-Small Cell Lung Cancer: Challenges Faced and Steps Forward.

48. Lifestyle Factors in Cancer Survivorship: Where We Are and Where We Are Headed.

49. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.

50. Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.

Catalog

Books, media, physical & digital resources